The success of Viagra initially drove a period of growth for the drug industry, however recent shifts present a murky scenario for shareholders. Off-patent alternatives are reducing earnings, and persistent litigation https://dillancpyq706066.newsbloger.com/41798799/the-blue-pill-and-pharma-a-risky-bet